CompletedNot applicableNCT02440139
Official study title

Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC

Study summary

STUDY DESIGN: This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is superior to the unaided reader for detecting actionable lung nodules. Secondary: The secondary objective of this clinical study is to prove that the reader's reading time is not significantly increased when aided with CRCTI. NUMBER OF SUBJECTS: Retrospective CT studies from approximately 300 patients will be included in the study. Approximately 100 true positive cases and 200 normal cases. NUMBER OF READERS: A reader study with at least ten (10) participating radiologists (US Board Certified) will be conducted. PRIMARY ENDPOINTS: Scores given by the radiologists with and without ClearRead CT Insight will be recorded and compared to the true status of the study-cases. The frequency of the scores for each method (Unaided, Aided) will be tabulated and LROC curves constructed along with sensitivity, specificity, PPV, NPV and clinical actions. Additionally, machine nodule detection rate and false positives per patient on normal cases will be measured. PATIENT POPULATION : The study will target approximately one hundred (100) patients whose CT nodules were shown to be cancer and two hundred (200) normal patients. The patient population will be consistent with the national lung cancer screening protocols.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedClearRead CT Insight

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 4, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Virginia Polytechnic Institute and State University

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
Virginia Polytechnic Institute and State University
Interventions being studied
Device: ClearRead CT Insight
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

A thoracic CT case that is associated or with a feature of the following: 1. Asymptomatic patients age 55 - 77 with history of smoking 2. Primary Lung Cancer 3. Biopsy Proven (LuRADS 5) with radiology report 4. Screen detected event plus 1 prior CT. 2 year of prior CTs is preferred, if available. 5. \<= 3mm slice spacing, no gaps 6. Use standard reconstruction kernels 7. Maximum of 5 nodules per image 8. Nodules must be 5-20mm in size 9. With or without contrast

Reasons someone may not be able to joinExclusion criteria

Thoracic CT cases that meet the following

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Arlington Innovation Center: Health ResaerchArlington, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 4, 2021. Always confirm current availability with the study team.

View original record ↗